A clinical-stage biotech company developing new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Our first two indications are for (i) mild traumatic brain injury (“mTBI”), known as concussion, and (ii) the cognitive decline, lethargy and “brain-fog” associated with Covid-19 infection, known as Covid Longhauler syndrome (“Long Covid”).
